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Abstract
Background: Breast cancer is a collection of diseases in which molecular phenotypes can act as both indicators
and mediators of therapeutic strategy. Therefore, candidate therapeutics must be assessed in the context of
multiple cell lines with known molecular phenotypes. Docosahexaenoic acid (DHA) and curcumin (CCM) are dietary
compounds known to antagonize breast cancer cell proliferation. We report that these compounds in combination
exert a variable antiproliferative effect across multiple breast cell lines, which is synergistic in SK-BR-3 cells and
triggers cell signaling events not predicted by the activity of either compound alone.
Methods: Dose response curves for CCM and DHA were generated for five breast cell lines. Effects of the DHA+
CCM combination on cell proliferation were evaluated using varying concentrations, at a fixed ratio, of CCM and
DHA based on their individual ED50. Detection of synergy was performed using nonlinear regression of a sigmoid
dose response model and Combination Index approaches. Cell molecular network responses were investigated
through whole genome microarray analysis of transcript level changes. Gene expression results were validated by
RT-PCR, and western blot analysis was performed for potential signaling mediators. Cellular curcumin uptake, with
and without DHA, was analyzed via flow cytometry and HPLC.
Results: CCM+DHA had an antiproliferative effect in SK-BR-3, MDA-MB-231, MDA-MB-361, MCF7 and MCF10AT
cells. The effect was synergistic for SK-BR-3 (ER
- PR
- Her2
+) relative to the two compounds individually. A whole
genome microarray approach was used to investigate changes in gene expression for the synergistic effects of
CCM+DHA in SK-BR-3 cells lines. CCM+DHA triggered transcript-level responses, in disease-relevant functional
categories, that were largely non-overlapping with changes caused by CCM or DHA individually. Genes involved in
cell cycle arrest, apoptosis, inhibition of metastasis, and cell adhesion were upregulated, whereas genes involved in
cancer development and progression, metastasis, and cell cycle progression were downregulated. Cellular pools of
PPARg and phospho-p53 were increased by CCM+DHA relative to either compound alone. DHA enhanced cellular
uptake of CCM in SK-BR-3 cells without significantly enhancing CCM uptake in other cell lines.
Conclusions: The combination of DHA and CCM is potentially a dietary supplemental treatment for some breast
cancers, likely dependent upon molecular phenotype. DHA enhancement of cellular curcumin uptake is one
potential mechanism for observed synergy in SK-BR-3 cells; however, transcriptomic data show that the
antiproliferation synergy accompanies many signaling events unique to the combined presence of the two
compounds.
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Breast cancer is now understood to be a collection of
diseases characterized by malignant cells of different
molecular phenotypes. Tumor subtypes are primarily
categorized by expression of three cellular receptors:
estrogen receptor (ER, HGNC gene symbol ESR1), pro-
gesterone receptor (PR, HGNC gene symbol PGR), and
the epidermal growth factor receptor family member
Her2/Neu (HGNC gene symbol ERBB2). Expression
levels of all three cellular receptors are emerging as indi-
cators of disease prognosis and criteria for determina-
tion of appropriate therapeutic regimen [1-5]. Because
of this increased attention is being given to therapeutic
strategies targeted to breast cancers based upon molecu-
lar subtypes [6-10]. Therefore, it should not be surpris-
ing that compounds exhibiting some utility as
antiproliferation agents can show variable results when
applied to cell lines of different ER/PR/Her2 phenotype.
In fact, in an extensive characterization of the genetic
and phenotypic variation among 51 breast cancer cell
lines, Neve et al. even demonstrated variable potency of
Trastuzumab among three Her2-overexpressing cell
lines, with therapeutic response prediction later refined
by post-hoc analysis of expression level for several other
proteins and amplification of various chromosomal
regions [11]. It stands to reason that investigation of
anti-cancer dietary compounds will also benefit from a
detailed look at interaction with cancer cell molecular
phenotype. Only then will proper tailoring of dietary
supplemental treatment to breast cancer subtype be
facilitated. In this study we show that a combination of
curcumin (CCM) and docosahexaenoic acid (DHA)
results in variable antiproliferative effects across breast
cancer cell lines of different molecular phenotype. For
S K - B R - 3 ,t h ec e l ll i n ef o rw h i c ht h ee f f e c ti sas y n e r g i s -
tic improvement over either compound individually, the
effect is accompanied by transcript and protein level
changes that are not simply a combination of changes
caused by either molecule alone.
DHA is an omega-3 fatty acid (22:6
Δ4,7,10,13,16,19), part
of a family of compounds reputed to possess many
human health benefits, including anticancer properties
[12]. Early epidemiological evidence strongly linked fish
oil (rich in DHA and eicosapentaenoic acid) with low-
ered incidence of several types of cancer, including
breast cancer [13-16]. In addition to epidemiological
studies, dietary studies with mice and humans, com-
bined with numerous tissue culture studies, have sub-
stantiated the beneficial role of DHA in breast cancer
[17-20]. DHA induces apoptosis in cancer cells through
multiple mechanisms [21-27]. DHA also induces cell
cycle arrest through p21-mediated inhibition of cyclin-
dependent kinase-2 (CDK2) activity and stimulates pro-
tein phosphatase activity [20,28]. In addition, transport
of DHA and other fatty acids to the nucleus and binding
t on u c l e a rr e c e p t o r ss u c ha sp eroxisome proliferator-
activated receptor (PPAR) and retinoid X receptors
(RXRs) have been reported. DHA is a general ligand of
PPARs, but binds more selectively to RXR transcription
factors [29]. RXRs form homo- or heterodimers with
PPAR and other nuclear hormone receptor super-
families that include receptors for steroids, thyroid hor-
mones, retinoic acid and vitamin D. RXRs are in turn
reported to regulate p21 expression in breast cancer
MDA-MB-231 cells [30]. These recent developments
suggest that DHA may also play a role in attenuation of
breast cancer growth through a PPARg/RXR-mediated
mechanism. Finally, DHA down regulates CXCR4, indi-
cating ability to reduce the metastatic potential of breast
cancer cells by decreasing the surface expression of a
pro-migratory molecule [31].
CCM [1,7-bis(4-hydroxy-3-methoxy phenyl) -1,6-hep-
tadiene-3,5-dione] is a biphenyl compound naturally con-
centrated in the rhizome of the herb Curcuma longa,
commonly known as turmeric in English, haldi in Hindi,
and ukon in Japanese. CCM has been used in Asian med-
icine for over 3,000 years [32], and possesses a wide
range of pharmacological activities including anti-inflam-
matory, anticancer, antioxidant, wound healing, and anti-
microbial effects [33]. The pharmacology and putative
anticancer properties of CCM have been extensively
reviewed [34-38]. Preclinical studies have revealed che-
mopreventive potential of CCM for several cancers,
including colon [39,40], duodenal [41], stomach [42],
prostate [43], and breast [44]. CCM has been shown to
block each step in the carcinogenesis process, namely
tumor initiation, promotion, and progression [45]. CCM
acts on multiple targets and inhibits activation of key cell
signaling mediators, including NFB( N F B), AP-1, Cox-
2, MMP9, PKC, and EGFR [38]. CCM dramatically
induces transcription of PPARg and activates PPARg in
hepatic stellate cells [39]. CCM regulates p21 expression
through a p53-dependent pathway in several cellular
models, including breast cancer cells [44,46-49]. CCM’s
antiproliferative effects, specifically on breast cancer cells,
have been linked in multiple ways to the induction of
apoptosis. For example, downregulation of c-Jun N-term-
inal kinase (JNK), upregulation of BAX as an effector of
p53, downregulation of Bcl-2, inhibition of Akt/PKB, and
generation of reactive oxygen species (ROS) have all been
observed in breast cancer derived cell lines exposed to
curcumin [23,50-52].
It is clear that DHA and CCM independently have
biological activities that warrant development for thera-
peutic purposes, and combinations of the two have even
been reported to exert synergistic effects against colon
cancer inflammation and growth of pancreatic tumor
xenografts [53,54]. However, productive application of
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requires: (1) comparison of cell lines representing dis-
tinct molecular phenotypes associated with disease sub-
classes, (2) quantitative methods for detection of synergy
versus additive effects upon cell proliferation, and (3)
molecular characterization of cellular response sufficient
to show whether any detected synergy is based upon
novel mechanisms versus a straightforward merger of
effects expected of each molecule individually. Accord-
ingly, this study included five breast cell lines covering
distinct cellular receptor expression phenotypes: SK-BR-
3( E R
- PR
- Her2
+), MDA-MB-231 (ER
- PR
- Her2
-),
MDA-MB-361 (ER
+ PR
- Her2
+), MCF7 (ER
+ PR
+ Her2
-)
and MCF10AT (ER
+,P Ri s o f o r mBb u tn o tA ,H e r 2
variable) [11,55-58]. Across these cell lines, the antipro-
liferation effects of CCM, DHA, and a CCM+DHA com-
bination were assessed quantitatively using methods
designed specifically to detect the presence of synergistic
versus additive or subadditive action. Detection of anti-
proliferation synergy for CCM+DHA within the SK-BR-
3 cell line was followed by transcript analysis using the
Agilent Whole Human Genome Microarray 4 × 44 K
platform, demonstrating a broad gene regulatory
response across several functional categories that have
little in common with transcript level changes caused by
CCM or DHA alone. Two protein level phenomena that
could be expected from CCM and DHA individually,
PPARg expression and p53 phosphorylation, were both
increased in the presence of CCM+DHA over levels
observed for either compound alone. Finally, in addition
to the combination causing novel intracellular molecular
responses, DHA directly enhanced cellular uptake of
CCM as demonstrated by flow cytometry and HPLC
techniques. This suggests an added benefit of the com-
bination in that, while DHA can achieve fairly high sys-
t e m i cc o n c e n t r a t i o ni nh u m a n s ,C C Mo ni t so w nh a s
limited bioavailability.
Methods
Cell lines and reagents
All cell lines were obtained from the American Type
Culture Collections (ATCC; Manassas, VA) unless
otherwise noted. MDA-MB-231, MDA-MB-361, and
MCF7 cells were maintained in Dulbecco’sm o d i f i e d
eagle medium (DMEM; Invitrogen; Carlsbad, CA) sup-
plemented with penicillin (100 units/ml), streptomycin
(100 μg/ml) and 10% FBS. SK-BR-3 cells were main-
tained in McCoy’s 5A medium (ATCC) supplemented
with penicillin (100 units/ml), streptomycin (100 μg/ml)
and 10% FBS. MCF10AT cells were purchased from
Barbara Ann Karmanos Cancer Institute (Detroit, MI)
and maintained in DMEM/F12 (Invitrogen; Carlsbad,
CA) supplemented with penicillin (100 units/ml), strep-
tomycin (100 μg/ml), 5% horse serum, insulin (10 μg/
ml), epidermal growth factor (20 ng/ml), hydrocortisone
(0.5 μg/ml), and cholera toxin (100 ng/ml). These sup-
plemented media are referred to as complete media. All
cell cultures were incubated in a humidified incubator
at 37°C and 5% CO2. The pan-caspase inhibitor Z-VAD-
FMK was purchased from Biovision (Mountain View,
CA). DHA (NuChek Prep, Inc., Elysian, MN) was
diluted in 100% ethanol to make 50 mM stock solutions.
CCM (Sigma Aldrich, St. Louis, MO) was dissolved in
DMSO to make 50 mM stock solutions. Stock solutions
of DHA and CCM were further diluted in respective
media prior to cell treatment. Final concentration of
ethanol or DMSO in treated cells was less than 0.1%.
Proliferation assays
Cells were seeded into 96 well plates (5 × 10
3/well) in
complete medium one day prior to treatment. For MDA-
MB-231, MDA-MB-361, and MCF7, treatments with
DHA, CCM, or CCM+DHA were done in DMEM sup-
plemented with 2% FBS. For SK-BR-3, treatments were
done in McCoy’s 5A medium supplemented with 2%
FBS. For MCF10AT, treatments were done in complete
medium. All cells were treated for 24 hours at 37°C/5%
CO2 with indicated concentrations of DHA,CCM or
CCM+DHA along with cells treated with similar concen-
trations of ethanol and/or DMSO (less than 0.1%) as
matching vehicle controls. Proliferation was analyzed
using WST-1 assays in accordance with the manufac-
turer’s instructions (Roche Biosciences, Indianapolis, IN).
Analysis of synergy
Proliferation results were analyzed as previously
described [59] with some modification. Pilot assays were
carried out individually for DHA and CCM with each
cell line in order to determine ED50 for each reagent
(Table 1). Using the ratio of the ED50s, the proportion
of each compound needed in a combination dose was
calculated with the constraint that each compound
account for 50% of the combination’sp o t e n c y .A s
described by Tallarida, for each observed percent effect
Table 1 ED50 values for DHA and curcumin effects on
breast cancer cell lines
Combination
Initial ED50 (μM)
a Ratio (μM)
Cell Line DHA CCM DHA:CCM
MCF7 56.5 ± 8.2 28.0 ± 4.2 55:30
MCF10AT 93.2 ± 5.5 45.8 ± 2.5 95:45
MDA-MB-231 36.7 ± 6.5 34.7 ± 10.4 35:35
SK-BR-3 63.8 ± 1.5 39.2 ± 1.8 60:40
MDA-MB-361 52.5 ± 9.5 23.0 ± 4.2 50:25
aInitial ED50 values calculated as mean ± SD concentration required for 50%
inhibition of proliferation from two independent triplicate assays.
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additive dose was found [59]. Experiments were then
carried out using the fixed ratio combination of DHA
and CCM at a variety of different doses. For both indivi-
dual compounds, the actual combination, and the theo-
r e t i c a la d d i t i v ed o s e s ,d o s er e s p o n s ec u r v e sw e r ef i t
using GraphPad Prism (GraphPad Software Inc., La
Jolla, CA). For each, a four-parameter dose response
curve was fit using non-linear regression [60]. To evalu-
ate the potential synergy between the compounds, the
least squares fit line for the theoretical additive curve
and the actual CCM+DHA mixture were plotted on the
same axes, and the two curves were compared using
parameter estimates and their respective 95% confidence
intervals. If the actual combination had a much different
effect than expected, it was indicated by either a statisti-
cally significant shift in the ED50 or hillslope.
Analysis of synergy by combination index (CI)
The Loewe additivity model was used as a second
method of analyzing the interaction between DHA and
CCM [61]. The interaction between the compounds is
reported as the combination index in the following
equation:
CI = (d1/Dx,1) + (d2/Dx,2)
In the equation, d1 and d2 represent the concentra-
tions of the compounds in combination required to
achieve x effect. Dx,1 and Dx,2 represent the concentra-
tions of the same compounds individually that would
quantitatively achieve the same x effect. A CI < 1.0 indi-
cates that the combination is synergistic, and a CI > 1.0
indicates an antagonistic interaction. The combination
indexes for this study were determined by using concen-
trations corresponding to the ED50 of dose response
curves for DHA, CCM or CCM+DHA.
Cell culture and treatments for whole human genome
transcript level analysis
SK-BR-3 cells were plated in 6 well plates (2.5 × 10
5/
well) in complete medium overnight prior to treatment.
Cells were treated with vehicle or with 30 μMD H A ,3 0
μM CCM, or CCM+DHA (12 μM CCM + 18 μM DHA)
for 24 hours with nine replicates per treatment. Follow-
ing treatment, the cells were washed three times with
PBS and suspended in 500 μl Trizol Reagent (Roche
Biosciences; Indianapolis, IN). The suspended cells were
pooled in sets of three, resulting in triplicates for each
condition. The samples were frozen at -80°C.
Transcript level data collection and pre-processing
Cells in Trizol were shipped on dry ice to Miltenyi Bio-
tec Genomics Services (MBGS) for analysis via a one-
color Agilent Whole Human Genome Oligo Microarray
platform. RNA processing, array hybridization, image
collection and data processing were executed according
to protocols described in the MBGS Service Report.
Briefly, total RNA was isolated using a standard Trizol
protocol and evaluated for quality on an Agilent 2100
Bioanalyzer platform. Cy3-labeled cRNA was produced
using the Agilent Low RNA Input Linear Amp Kit (Agi-
lent Technologies) following the manufacturer’sp r o t o -
col. Yields of cRNA and the dye-incorporation rate were
measured with the ND-1000 Spectrophotometer (Nano-
Drop Technologies). The hybridization procedure was
performed according to the Agilent 60-mer oligo micro-
array processing protocol using the Agilent Gene
Expression Hybridization Kit (Agilent Technologies) and
Agilent’s recommended hybridization chamber and
oven. Microarray Cy3 images were read and pre-pro-
cessed for background subtraction using Agilent’s Fea-
ture Extraction Image Analysis Software (FES). Inter-
chip scaling and differential gene expression calls were
produced by analyzing FES-produced feature signal
intensities with Rosetta Resolver (Rosetta Biosoftware).
For each chip feature, significance of difference between
control and experimental conditions was tested by
applying an error model-based hypothesis test to all
control replicates as a group versus each treatment
replicate individually. Theory and validation of this
method are described in Weng et al., 2006 [62]. The
error model-based test results in a P value associated
with the difference observed for each feature; difference
values are reported as both log10 ratio and fold change
of experimental signal intensity over control signal
intensity.
Processing of preselected candidate gene lists and gene
ratio lists from MBGS
Hypothesis tests from Rosetta Resolver were reported
for all array features under each treatment condition;
these results were further sorted by MBGS to produce
files containing preselected candidate gene lists (PCGL)
for all three replicates of each treatment condition. Each
PCGL includes all array features returning a fold change
≥ 2 (up or down) with an associated P value ≤ 0.01.
This does not unambiguously resolve all responses on a
gene-by-gene basis as individual genes may be repre-
sented by multiple features within the Agilent array and
that some individual genes could be represented by mul-
tiple features that returned contradictory responses.
Therefore, the process of isolating genes with unambig-
uous transcript level responses required further logical
filtering of the Rosetta Resolver results.
PCGL results for each experimental condition were fil-
tered to return features showing fold change in the same
direction in all three replicates. For these features, fold
Altenburg et al. BMC Cancer 2011, 11:149
http://www.biomedcentral.com/1471-2407/11/149
Page 4 of 16change and P value were averaged across the three repli-
cates. All P values are ≤ 0.01, but for cases in which a
gene is represented by multiple features responding in
the same direction we used mean P value as a decision
rule for which fold change value to attribute to the cor-
responding gene. These features were then sorted
according to gene identity. Genes were subsequently fil-
tered using a conditional formula that removed genes
with contradictory features and, within each gene,
returned fold change values associated with features
exhibiting the smallest mean P value.
We then constructed matrices of fold change values,
allowing comparison of the responses of individual genes
among treatments for the purpose of heatmap genera-
tion. Any gene that responded significantly to only one
or two treatments required retrieving fold change values
< 2.0 from the whole-array gene ratio files. To do this, we
assembled a cumulative list of Gene IDs including all
genes that responded with fold change ≥ 2.0, P ≤ 0.01, in
at least one treatment. For a specific treatment, genes
showing significant response were removed from the
cumulative list, and remaining Gene IDs were used to
query the whole-array gene ratio list for that treatment.
In order to do this, gene ratio files from the three repli-
cates of a treatment were combined, and means were cal-
culated for the ratios and P values of all features. The set
of gene IDs was then used to extract relevant feature data
from the set of averaged feature data. Finally, a set of fold
change values and P values was assembled, for a treat-
ment condition, showing both genes that responded to
that treatment and values for genes that did not have sig-
nificant responses ≥ 2.0 in that treatment, but did in at
least one of the other two treatments. This set of results
supplied the values used to create the heatmap (see
results section). Examples of the spreadsheets used to
process the microarray data are available in the supple-
mental files (Additional file 1, 2, 3, 4, 5).
Reverse transcript polymerase chain reaction
SK-BR-3 cells were plated in 6 well plates (2.5 × 10
5/well)
in complete medium overnight prior to treatment. Cells
were treated with vehicle or with 30 μMD H A ,3 0μM
CCM, or CCM+DHA (12 μMC C M+1 8μMD H A )f o r
24 hours with nine replicates per treatment. Following
treatment, the cells were washed three times with PBS and
trypsinized. The cells were pooled in sets of three, result-
ing in triplicates for each condition. RNA was isolated
using the RNeasy mini kit (Qiagen) according to manufac-
turer protocol. Complementary DNA was generated using
Superscript III reverse transcriptase (Invitrogen) according
to manufacturer protocol. PCR reactions were performed
with 1 minute, 94°C, followed by 30 cycles of [1 minute,
94°C; 1 minute, 56°C; 1 minute, 72°C] followed by 5 min-
utes, 72°C. Primers for PCR reactions are listed in table 2.
PCR products were visualized on 1% agarose gels. 15s
ribosomal RNA was used as a loading control.
Western blot analysis
SK-BR-3 cells were seeded into 6 well plates (2.5 × 10
5/
well) in complete medium one day prior to treatment.
Following 24 hour treatments with 30 μMD H A ,3 0μM
CCM, or a mixture containing 12 μM CCM and 18 μM
DHA, the cells were lysed with RIPA lysis buffer con-
taining pervanadate (200 μM), NaF (1 mM), diisopropyl
fluorophosphates (DIFP), and protease inhibitors (Roche
Biosciences, Indianapolis, IN). Protein concentrations
were normalized using BCA reagent according to the
manufacturer’s protocol (Pierce, Rockford, IL). SDS-
PAGE membranes were probed with antibodies to p21,
p53 and phospho-p53 (Cell Signaling Technologies,
Danvers, MA), PPARg and GAPDH (Santa Cruz Bio-
technologies, Santa Cruz, CA).
Curcumin uptake
The ability of each cell line to absorb CCM was quanti-
fied using flow cytometry. Cells were treated for 24 hours
with escalating concentrations of CCM or combinations
of DHA and CCM in McCoy’s5 Aw i t h2 %F B Sa ti n d i -
cated concentrations. Cells were then trypsinized and
washed three times with cold PBS. Because CCM exhibits
a green fluorescent signal [63,64], the cells were analyzed
using the FL1 channel of a FACSCalibur flow cytometer
(Becton Dickinson; Franklin Lakes, NJ) equipped with an
air-cooled argon laser emitting at 488 nm wavelength.
Fluorescence was detected through a 575 ± 26 nm band
pass filter and quantified using CellQuest Software (Bec-
ton Dickinson; Franklin Lakes, NJ). Quantification results
are presented as percent increase of the mean fluores-
cence intensity of the CCM treated samples, compared to
untreated controls in triplicate assays, using gated cell
populations that exclude dead cells and cellular debris.
Quantification of curcumin uptake by HPLC
Quantification of CCM uptake by HPLC was performed
to validate the flow cytometry method. Confluent cells
Table 2 Primers for PCR reactions
Gene Forward primer Reverse primer
CYP1A1 5’-ggactttaacccctacaggtatgt-3’ 5’-ggatctttctctgtaccct
ggggtt-3’
CYP1A2 5’-cagaatgccctc
aacaccttctccatcg-3’
5’-gtgatgtcccggaca
ctgttcttg-3’
CYP1B1 5’-gagaacgtaccggcca
ctatcact-3’
5’-gttaggccacttca
gtgggtcatgat-3’
SERPINB5 5’-cttgcctgttccttttccac-3’ 5’-tggagagtttgaccttggca-3’
CXCR4 5’-ggtggtctatgttggcgtct-3’ 5’-tggagtgtgacagcttggag-3’
15s rRNA 5’-ttccgcaagttcacctacc-3’ 5’-cgggccggccatgctttacg-3’
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hours. Following treatment, the cells were washed three
times with cold PBS and lysed with RIPA buffer. The
lysates were sonicated for 5 seconds. Cell lysate (200 μl)
and 20 μl internal standard solution (R6G in ethanol,
300 μg/ml) were added to a pyrex glass tube. Chloro-
form containing 0.05% BHT (7 ml), 3.5 ml methanol
containing 0.05% BHT and 1.7 ml 0.5 M KOAC-HAC
(1:1) buffer were added to the tube, vortexed for 1 min-
ute, and centrifuged at 900 × g for 10 min. The chloro-
form layer was harvested and dried under nitrogen gas
flow. The residue was dissolved in 200 μl ethanol and
transferred to an HPLC sample vial. CCM uptake was
analyzed by a reversed-phase HPLC method using a Shi-
madzu LC-20AT HPLC system equipped with a multi-
wavelength diode array detector (DAD), a SIL-20ACHT
autosampler, and an Ascentis
® C18 column (4.6 × 250
mm, 5 μm) (Supelco, Sigma-Aldrich; St. Louis, MO). A
gradient mobile phase composed of 45% acetonitrile
(0.1% TFA)-55% water (0.1% TFA) to 100% acetonitrile
(0.1% TFA) was used. The flow rate was 1.0 ml/min and
the detection wavelengths were 426 nm and 528 nm,
respectively, for CCM and rhodamine 6G (internal stan-
dard). The CCM peak was identified by comparing to
the reference standard, and the quantification of the
CCM was preceded with an external standard curve
combined with internal standard technology. The con-
centration of the CCM was normalized based on the
protein concentration of the cell lysate.
Statistics
Statistical analysis of data is described earlier for each
specific experiment. Otherwise all comparisons were
analyzed by ANOVA. P values less than 0.05 were con-
sidered significant. Triplicate experiments were repeated
at least three times.
Results
DHA and curcumin exert synergistic anti-proliferative
effects on SK-BR-3 cells
Initial cell proliferation assays were performed with dilu-
tion series (0-100 μM) of DHA and CCM using four
breast cancer cell lines and one line (MCF10AT) repre-
senting ‘premalignancy’, each with a unique pattern of
cellular receptor expression: SK-BR-3 (ER
- PR
- Her2
+),
MDA-MB-231 (ER
- PR
- Her2
-), MDA-MB-361 (ER
+ PR
-
Her2
+), MCF7 (ER
+ PR
+ Her2
-)a n dM C F 1 0 A T( E R
+,
PR isoform B but not A, Her2 variable). ED50 values
were determined for DHA and CCM, for each cell line,
and presented in Table 1. A combination of CCM+DHA
(with proportions of DHA and CCM derived from their
ED50 values) was used to measure the antiproliferation
effect for each cell line at different doses (0-100 μM) as
described by Tallarida [59]. The dose response curve for
CCM+DHA was then compared to the theoretical addi-
tive dose response curve to determine if the combina-
tion of CCM+DHA resulted in a synergistic effect. It
c a nb es e e nt h a tt h ec o m b i n a t i o no fC C M + D H A( 2 : 3
ratio) when used below 50 μM exerted a synergistic
effect only in the SK-BR-3 breast cancer cell line (Figure
1A). While there was no substantial difference in ED50
values, there was a significant difference in the hillslopes
[(-7.6; 95% CI (-10.2, -5.1) for the theoretical additive
curve and -1.9; 95% CI (-2.8, -1.0) for the actual mix-
ture)]. This indicates that the span of doses where the
actual combination of CCM+DHA is effective is much
greater than expected. The synergism between DHA
and CCM disappeared at higher doses, though a dose-
dependent antiproliferative effect was still present. CCM
+DHA also affected the MDA-MB-231, MDA-MB-361,
MCF7, and MCF10AT cell lines, but subadditive to
additive results were observed at all combinations tested
(Figure 1B-E). Extending the treatments to 48 hours had
no significant effect on the synergistic or subadditive
status of each cell line (data not shown). The synergistic
effect of CCM+DHA on SK-BR-3 cells was further con-
firmed using an alternative approach of calculating the
Combination Index. The combination of CCM+DHA at
concentrations below 50 μM had a Combination Index
< 1, indicating synergism between two compounds (Fig-
ure 2A). We further experimentally compared antiproli-
ferative effects of the combination with each compound
individually using an optimal concentration (30 μM)
and found that neither DHA or CCM were effective in
inhibiting cell growth, whereas 30 μMo ft h ec o m b i n a -
tion (18 μM DHA + 12 μM CCM) significantly inhibited
SK-BR-3 cell growth (Figure 2B).
DHA + Curcumin regulatory effects on genes of disease-
relevant functional groups
Transcript level changes were assessed for three repli-
cate SK-BR-3 cell populations for each of three 24 hour
treatment conditions: CCM (30 μM), DHA (30 μM) and
CCM + DHA (12 μM+1 8μM). The Agilent whole
human genome microarray results for each of the three
treatment conditions were compared with transcript
levels for SK-BR-3 cells left untreated in growth med-
ium for 24 hours. As described in Methods, Rosetta
Resolver was used to assign P values to individual chip
elements for differences between untreated and treated
cells using an error model-based hypothesis test. All
chip elements meeting the criteria of fold-change ≥ 2.0
(p < 0.01), in any experimental replicate, were further
filtered to return only transcripts for which at least one
chip element responded with 2-fold or greater change,
in the same direction, p < 0.01, with no other chip ele-
ment indicating a significant contradictory directional
change, across all three replicates for a treatment.
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Page 6 of 16According to these criteria, the numbers of transcripts
exhibiting significant change for each treatment are as
follows: CCM, 8,817; DHA, 61; CCM+DHA, 1,449
(Additional file 6).
The most striking initial result was that CCM+DHA
caused far fewer significant transcript level changes in
SK-BR-3 cells than CCM alone, even though CCM
+DHA had a greater antiproliferative effect. A cursory
examination of the data also showed that some of the
transcripts responding to CCM+DHA did not appear as
significant responders in either of the other two treat-
ments. Therefore, our strategy for an initial informatic
analysis of these data was to rank CCM+DHA respon-
ders by magnitude of change, place a minimum cutoff
at 5-fold (up or down), and annotate genes appearing
within this set according to known disease-relevant
functions. In addition, CCM+DHA responders below 5-
fold were scanned for genes of known relevance to anti-
proliferation processes, such as caspases. Figure 3 illus-
trates the results in the form of a heatmap divided into
functional blocks. This strategy recovered an interesting
picture showing 31 functionally diverse transcript regu-
latory responses, many of which are unique to the CCM
+DHA combination. We observed that genes involved
in tumor progression/growth, cell cycle progression,
metastasis, and anti-apoptosis/survival were synergisti-
cally downregulated by the combination, while genes
involved in apoptosis, tumor suppression, and inhibition
of metastasis were synergistically upregulated. Interest-
ingly, we also found a group of cytochrome p450 genes
(1A1, 1A2, 1B1), which are involved in enhancement of
anti-cancer effects of small molecules, including some
dietary compounds (see discussion below). Results from
the microarray transcript analysis were further validated
by RT-PCR for selected genes, and our results (Figure
3B) have validated changes observed within the microar-
ray data. RT-PCR also confirmed that CYP1A1/CYP1A2
a n dC X C R 4d i dn o tr e s p o n dt oD H Ao rC C Ma l o n e ,
but their expression was stimulated or reduced, respec-
tively, by combined DHA+CCM treatment (Figure 3B).
Similarly, RT-PCR data also verified other directional
changes indicating that the CCM effect on CYP1B1 was
reversed by CCM+DHA, whereas SERPINB5 expression
was enhanced following CCM+DHA treatment. While it
is important to confirm expression levels of proteins
directly before concluding specific signaling mechan-
isms, the genome-wide study of transcript and protein
level correlation by Shankavaram et al. demonstrates
predictive power of transcripts for protein levels across
the NCI60 cell line panel[65]. Therefore, as a hypothesis
building tool, transcript screens serve as valuable indica-
tors of relevant network areas to study further.
SERPINB5 and CYP1A1/1A2/1B1 are transcripts of
special functional interest. SERPINB5 produces a protein
Figure 1 The effects of DHA and CCM on breast cancer cell
line proliferation. SK-BR-3 (A), MDA-MB-231 (B), MDA-MB-361 (C),
MCF7 (D), and MCF10AT (E) cell lines were treated for 24 hours with
escalating doses of DHA (blue line), CCM (green line), or a 2:3 ratio
of CCM+DHA (black line). A theoretical additive curve (red line (A))
was generated based on the curves for the individual compounds.
Proliferation was measured with the WST-1 assay according to
manufacturer protocol. Nonlinear regression of sigmoid dose-
response model was performed with GraphPad Prism software.
Results represent combinations of at least three triplicate
experiments.
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Page 7 of 16Figure 2 The synergistic effect of CCM+DHA on SK-BR-3 proliferation. (A) Combination index (CI) calculated for the SK-BR-3 cell
proliferation. (B) Direct comparisons of 30 μM treatments with CCM and DHA individually with 30 μM treatment using the 2:3 ratio CCM+DHA
combination. P < 0.05 for three triplicate experiments.
Figure 3 Transcripts of functional importance relative to the synergistic antiproliferative effect of the curcumin/DHA combination. (A)
All genes are labeled according to current HGNC symbols. Numbers to the right of gene symbols indicate references in a separate transcript
annotation bibliography (see Additional file 8). Fold-change and associated P values corresponding to this figure can be found in Additional file
9. Heatmap values are log2-transformed, normalized fluorescence ratios for untreated versus treated cells (see methods), with green indicating
upregulation and red indicating downregulation relative to untreated SK-BR-3 cells. All responses shown for DHA+CCM were 2-fold or greater, p
< 0.01, on three replicate arrays. For the purpose of visual comparison within a heatmap format, values for non-significant responses are mean
normalized fluorescence ratios from three replicate arrays. For genes represented by more than one chip feature in the Agilent platform, mean
normalized fluorescence ratio was retrieved for the feature producing the lowest mean P value. As such, some responses in this figure appear
greater than 2-fold but were not significant according to the criterion p < 0.01. (B) RNA was isolated from SK-BR-3 cells treated with 30 μM DHA,
μM CCM, or a mix of 12 μM CCM+18 μM DHA. RT-PCR was performed for selected genes in order to validate the microarray data. Results are
representative of three separate experiments.
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Page 8 of 16also known as maspin, and is thought to be a major
downstream effector for the tumor suppression effect of
Tamoxifen [66-68]; therefore, it is possible that CCM
+DHA modulates a pathway overlapping that of Tamox-
ifen. CYP1A1/1A2/1B1 are members of the cytochrome
P450 family. They are thought to enhance the anticancer
effects of some small molecules, including dietary com-
pounds, by metabolizing them into other structures with
additional antiproliferative effects [69-72].
CCM+DHA effects are mediated through an apoptotic
process
As shown above, our data clearly indicated an induction
of genes involved in apoptosis. In order to further vali-
date contribution of apoptosis to the reduction of cell
proliferation during CCM+DHA treatment, we used a
pan-caspase inhibitor (Z-VAD-FMK) to inhibit initiation
of the apoptotic process. Data shown in Figure 4 indi-
cate that CCM and DHA, in varying concentrations of a
fixed 2:3 ratio, inhibited cell proliferation in a dose
dependent manner (20-90 μM), and the pan-caspase
inhibitor significantly reduced the effect of CCM+DHA
at all concentrations tested.
Protein level mediators of CCM+DHA synergistic effect
One common mediator for DHA and CCM is the cell
cycle regulator p21. In contrast to our prediction, we
found that DHA and CCM alone or in combination do
not increase p21 protein expression in SK-BR-3 cells
( F i g u r e5 A ) ,b u tc a ni n c r e a s ep 2 1i nt h eM D A - M B - 2 3 1
cell line (data not shown). As mentioned in the
introduction, CCM has been previously reported to
affect p53 activity, and DHA is known to be a ligand for
PPARg; therefore, we investigated the roles of expression
and activation for p53 and PPARg by DHA, CCM or the
combination relative to their synergistic growth inhibi-
tory effects. We observed that treating SK-BR-3 cells
with 30 μM CCM+DHA (2:3 ratio) resulted in increased
phosphorylation of p53 and increased expression of
PPARg (Figure 5A). These increases were not detected
when the cells were treated with 30 μM DHA alone,
and the effects were lower with 30 μM CCM alone.
Increases in p53 phosphorylation and PPARg expression
were not observed in MCF7 cells with identical treat-
ments (Figure 5B), suggesting that the effects are speci-
fic for the SK-BR-3 cell line. When treated with a
dilution series of either DHA or CCM alone, phosphory-
lation of p53 and upregulation of PPARg only occurred
with CCM treatment (Figure 5C), which suggests that
the DHA portion of the combination enhanced CCM-
mediated effects through the p53 and PPARg pathway.
Effects of DHA on curcumin uptake
While the mechanism of CCM entry into cells is
unknown, we have analyzed the differences among four
breast cancer cell lines for ability to absorb CCM. We
quantified CCM uptake by flow cytometry as CCM is
known to fluoresce in the green band [63,64]. In order
to validate the flow cytometry results, HPLC analysis
was also performed concurrently with initial flow cyto-
metry experiments (Figure 6A-B). The flow cytometry
data match trends seen in the HPLC results, but with
smaller dynamic range. SK-BR-3 cells treated with 20
μM CCM absorbed four-fold greater levels of CCM
than the MCF7 cells and 10-fold greater levels than the
MDA-MB-231 and MDA-MB-361 cells (Figure 6C).
Combining DHA with CCM further enhances the CCM
absorption of SK-BR-3 cells without significantly enhan-
cing CCM uptake in the other cell lines (Figure 6C).
This suggests that DHA enhancement of cellular per-
missiveness for CCM absorption is a potential mechan-
ism for the increased antiproliferative effects. It should
be noted that both HPLC and flow cytometry do not
distinguish CCM taken into the cell from CCM that is
bound to the cell surface. However, it is clear that the
SK-BR-3 cells exhibit a higher level of CCM fluores-
cence than the other cell lines and that the fluorescence
is increased in the presence of DHA. When viewed with
the data describing antiproliferative effect and molecular
level changes, it is unlikely that these data reflect only
CCM on cell surfaces.
Discussion
The idea that changes in diet or diet supplementation
may improve the health of cancer patients or enhance
Figure 4 CCM+DHA inhibit proliferation through a caspase-
mediated process. SK-BR-3 cells were pretreated for one hour with
20 μM Z-VAD-FMK, a pan-caspase inhibitor, prior to the addition of
escalating doses of CCM+DHA (2:3 ratios). After 24 hour incubation,
proliferation was analyzed with WST-1 reagent according to
manufacturer protocol. Results are representative of three separate
triplicate experiments. *P < 0.05 for Student’s t-tests comparing the
treatments with or without the pan-caspase inhibitor.
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motivation for exploring the activities of dietary com-
pounds. The translational process for such molecules
benefits from a relative lack of toxic side effects and
source material that is inexpensive and easily accessible
relative to synthetic pharmaceuticals. Human diets can
routinely encompass many biologically active small
molecules, and evidence for synergy between dietary
compounds is emerging [53,54,73]. In this study we
have presented data demonstrating that at low
concentrations, a combina t i o no ft h eo m e g a - 3P U F A ,
DHA, and curcumin, a molecule found in turmeric,
exerts a synergistic antiproliferative effect on the estro-
gen receptor negative, HER-2 positive SK-BR-3 breast
cancer cell line. The degree of synergy decreased, rela-
tive to activity of each compound alone, as concentra-
tion of the CCM+DHA combination was increased,
though total anti-proliferative effect continued to
increase with concentration. This observation has also
been made by others reporting synergy between DHA
Figure 5 Effects of CCM and DHA on p53 and PPARg. SK-BR-3 (A) and MCF-7 (B) cells were treated with 30 μM DHA, CCM, or the CCM+DHA
combination (12 μM CCM and 18 μM DHA) for 24 hours in 6 well plates. (C) SK-BR-3 cells were treated with escalating doses of CCM or DHA
individually. Cells were lysed and analyzed by SDS-PAGE. Blots were probed for phosphorylated p53, overall p53, p21, PPARg, and GAPDH as
indicated. Data are representative of three separate duplicate experiments.
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Page 10 of 16and CCM [53]. The fact that s y n e r g yi so b s e r v a b l ea t
low concentrations is of special interest in this case
because while the antiproliferative effects of CCM alone
may be more potent than those of DHA, CCM is
known to be poorly absorbed and has been observed to
remain under 2 μM in the serum and urine of human
subjects receiving several grams per day [74]. Conver-
sely, DHA can achieve plasma concentrations of
approximately 200 μM in humans administered daily
doses of oral DHA preparations over the course of a
month [75]. These human subject data become espe-
cially interesting as we have demonstrated a DHA
mediated enhancement of cellular CCM uptake. This
means that when DHA and CCM are used in combina-
tion, the intracellular concentration of CCM achievable
in vivo may not be limited to the concentration range
previously observed. Careful, tissue-specific pharmaco-
dynamics studies are needed to determine how our cell
culture results can translate to a clinical setting, but the
practical utility of this compound combination is
promising.
As mentioned above, breast cancer is a collection of
diseases with multiple phenotypes; therefore, one should
not expect that a particular therapeutic agent will con-
trol every malignancy subtype. The fact that only the
SK-BR-3 cell line was synergistically affected by DHA
Figure 6 Effect of DHA on CCM uptake. Cells were treated with 20 μM CCM for 24 hours. CCM uptake was quantified by flow cytometry (A)
in comparison with HPLC (B) as described in Materials and Methods. (C) SK-BR-3, MDA-MB-231, MDA-MB-361, MCF7, and MCF10AT cell lines
were treated with escalating doses of CCM in the presence or absence of 10 μM DHA and analyzed by flow cytometry. Fold changes (A, C) were
compared to respective cell line controls (without CCM or DHA). *P < 0.05 for Student’s t-tests comparing the treatments with DHA to the
treatments without DHA in three duplicate assays.
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an important factor for predicting efficacy. The ER
-/
Her2
+ phenotype is regarded as an aggressive tumori-
genic phenotype. Our data suggest that molecular phe-
notype has specific implications for efficacy, and
translation of these compounds into therapeutics will
require extensive mechanistic studies. Beyond demon-
strating the synergistic effect itself, the importance of
this study lies in the demonstration that observed
synergy is accompanied by cell signaling changes that
are unique to the combination of the two compounds.
A network state appears in which the aggregate of pro-
tein levels, protein states, and transcript levels are an
emergent property of the combined presence of DHA
and CCM.
T h er e s u l t ss h o w ni nF i g u r e s5a n d6d e m o n s t r a t e
that the synergistic effect of the CCM+DHA combina-
tion may in part be attributed to protein level effects
described for CCM alone, but that are increased in the
presence of DHA. CCM can increase the protein pool of
PPARg and increase phosphorylation of p53. Addition of
DHA further increases both of these molecular effects
and increases uptake of CCM by SK-BR-3 cells. This is
i n t e r e s t i n gi nt h a ti tf i t sap a t t e r no b s e r v e df o rD H Ai n
which it enhances the effects of other anti-cancer com-
pounds: 5-fluorouracil on colon cancer cells [76], cele-
coxib on prostate cancer cells [77], and doxorubicin [78]
in breast cancer. Our results, combined with previous
studies, suggest that part of DHA’sa c t i v i t yi st oa l t e r
cellular permissiveness for uptake of several kinds of
small organic molecules, possibly through alteration of
membrane lipid composition. Uptake of CCM and DHA
enhancement of this process were observed to be much
stronger in SK-BR-3 cells relative to four other breast
cancer cell lines, suggesting that the pharmacodynamics
of the CCM+DHA combination may be dependent
upon specific cancer phenotype, apart from the signaling
changes that occur once the compounds actually enter a
cell. Therefore, it is possible that the synergistic effect of
CCM+DHA on SK-BR-3 cells is dependent specifically
upon CCM uptake ability of this cell line, as opposed to
its cellular receptor expression state, but further study
of this distinction must account for the unique tran-
script-level regulation observed in the presence of CCM
+DHA and not CCM alone. In this study we did not
investigate the potential mechanism for CCM uptake by
different breast cancer cell phenotypes, which is clearly
a logical direction for our future studies.
Our microarray data suggest that cell cycle arrest and
apoptosis include contributions from other events
unique to the CCM+DHA combination upstream,
downstream, or independent of PPARg and phosphory-
lated p53. Two interaction networks were generated
within the MetaCore (GeneGo) network analysis
environment to illustrate all kinases documented as acti-
vators of p53 and all proteins documented to contribute
to upregulation of PPARg transcription (Additional file
7). From this it is clear that these two processes, while
stimulated by CCM alone, can be upregulated through
many alternate pathways. A 10-fold upregulation is seen
for NLRP1, DUSP13 and UCHL1, all positively asso-
ciated with apoptosis (see references in Additional file 8
for Figure 3) and all responding only to the CCM+DHA
combination. Similar results are seen for genes asso-
ciated with tumor suppression and MAP2, considered to
be anti-metastatic. Downregulation is observed for genes
associated with tumor progression, cell cycle progres-
sion, metastasis and anti-apoptosis/cell survival. Some of
these were downregulated only when both DHA and
CCM were applied to SK-BR-3 cells. Taken together,
these results suggest multiple mechanisms in addition to
enhanced CCM activity.
Two transcriptional responses of particular interest are
CYP1B1 and SERPINB5. CYP1B1 was actually downre-
gulated 2.4-fold by CCM alone, but this was reversed to
7.4-fold upregulation by the CCM+DHA combination
(see Additional file 9 for Figure 3). DHA alone had no
effect on this transcript. CYP1B1 is thought to contri-
bute to the anti-proliferative effects of several dietary
compounds by metabolizing them into products exhibit-
ing additional cytotoxicity within cancer cells [69-72].
Presence of wild-type CYP1B1 was reported to be asso-
ciated with protection against breast cancer in a popula-
tion of Indian women [79]. SERPINB5, the protein
product of which is also known as maspin, was upregu-
lated 18.9-fold when SK-BR-3 cells were treated with
CCM+DHA. Maspin is known to be upregulated by
tamoxifen and is considered to be a downstream effector
for the tumor suppression activity of tamoxifen [66-68].
It is, therefore, suggested that CCM+DHA induces an
anticancer effect through a mechanism that is shared by
tamoxifen. Furthermore, SK-BR-3 cells are ER-, raising
the question of whether the CCM+DHA combination
can contribute to overcoming tamoxifen resistance.
The anti-proliferative effect of CCM+DHA on SK-BR-
3 cells is validated as a true synergy by molecular level
characterization indicating that the emergent cell signal-
ing network state is unique to the combined use of the
two compounds. Transcript level responses are not an
additive result of changes that would be predicted based
upon activity of either compound alone. However, the
functionally categorized heatmap blocks presented in
Figure 3 are themselves only a beginning for the process
of determining a mechanism of action. This preliminary
analysis shows either transcript level changes that were
strong in magnitude, for genes of some known func-
tional description, or changes for which a direct connec-
tion with a process of interest is known, even if
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along with the synergistic antiproliferative effect demon-
strated for SK-BR-3 cells are a compelling collection of
disease relevant observations. However, the total gen-
ome-wide microarray data set requires network analysis
on a scale beyond the scope of this study. Given the col-
lection of strong transcript responses and the protein
pool/activation responses of what can be considered two
major signaling hubs (PPARg and p53), the complete set
of network nodes that mediate cellular response to
CCM+DHA is likely large and inclusive of multiple
pathways. Construction of a working model and subse-
quent experimental dissection of that model requires a
modular, carefully annotated assembly of molecular
responses into network neighborhoods in which both
interactive relationships and transcriptional response
values can be visualized. In this way, transcriptional
responses and changes in protein states can be studied
for patterns of causation that suggest much more speci-
fic mechanistic hypotheses than are apparent in a static
representation of expression data such as a heatmap.
Additionally, the observation of synergy in only one of
five different breast cancer cell phenotypes suggests that
signal paths critical to cell proliferation are not uni-
formly accessible to the CCM+DHA combination in all
breast cancer phenotypes. Determining the network of
interacting nodes responsible for the SK-BR-3 response
to CCM+DHA should in turn reveal a set of signaling
nodes that are candidates for being the root cause of
phenotypic differences among breast cancer types.
Conclusions
Our data suggest that combination of DHA and curcu-
min may provide a novel, effective dietary supplemental
treatment for some breast cancer patients, with a likely
dependency upon molecular phenotype. It is important
to stress that the synergistic antiproliferative effects
were only observed in the SK-BR-3 cell line. Analysis of
other breast cancer cell lines representing the ER
- PR
-
HER2
+ phenotype is required to confirm that the effect
is related to cancer subtype and not solely a property of
the SK-BR-3 cell line itself. In addition, there are breast
cancer cell lines that match SK-BR-3 cells with respect
to other characteristics (for example, expression of the
luminal versus basal gene clusters) [11], and the possibi-
lity that a mechanistic explanation of synergy lies within
these alternate characters is another immediate focus
for extension of this work. DHA enhancement of cell
permissiveness to curcumin uptake is one potential
mechanism for the observed synergy. However, our
microarray analysis suggests that some mechanistic
pathways are triggered in the presence of the curcumin/
DHA combination and do not appear when either com-
p o u n di su s e da l o n e ,i n d i c a t i n gt h a ta tl e a s tp a r to ft h e
observed synergy is an emergent property of the combi-
nation specifically. Although this study, as conducted in
an in vitro system, has certain limitations, a set of
unique genes was identified for the synergistic effect of
DHA and CCM. Studies in an in vivo system are cur-
rently underway to further validate the findings of the
present study.
Additional material
Additional file 1: Extracting three-replicate responsive genes from
Miltenyi Biotec microarray data. The Excel file “Supplementary Data-
1.1.xlsx” demonstrates the first step in logical filtering of preselected
candidate gene lists (PCGL) that are provided as pre-processed
microarray data by Miltenyi Biotec. Each PCGL is a list of the microarray
elements that returned a significant response within one replicate of a
treatment (fold change ≥ 2 and P ≤ 0.01). Most transcripts (genes) are
represented by more than one microarray element, and these do not
always agree with each other, rendering the result for a gene
ambiguous. Also, a single microarray address may not return the same
result across all three replicates. Therefore, logical filters were
implemented as conditional statements in Excel to compile a list, for
each treatment, of only those genes that respond significantly in a
consistent direction across three treatment replicates. Step one for the
Zadd treatment (CCM+DHA) is presented as an example.
Additional file 2: Extracting identities of genes that did not respond
to one treatment but did respond to another treatment. In order to
assemble the heatmap in Figure 3, it was necessary for each gene to
have a cell value across all three treatments, including those instances in
which a particular gene had no response to a given treatment. The Excel
file “Supplementary Data-1.2.xlsx” demonstrates, for the Zadd treatment,
how to assemble the list of microarray elements that were isolated as
three-replicate responders for either of the other two treatments, but
that returned no significant response for all three replicates of the Zadd
treatment. This list is used in the next step to query the raw data for
Zadd in order to collect fold-change values for these elements.
Additional file 3: Extracting ratio, fold-change and P values for
genes that did not respond to one treatment but did respond to
another treatment. The microarray element identities compiled in
Supplementary Data-1.2 were then used in “Supplementary Data-1.3.xlsx”
to query the gene ratio lists (comprehensive data for all microarray
elements) for each replicate of the Zadd treatment. Results for each
element are compiled into a single final data set sorted by element ID.
Additional file 4: Mean ratio, fold-change and P values for “ALL not
Zadd” microarray element list, checked against three-replicate
responders for Zadd. In the Excel file “Supplementary Data 1.4.xlsx”,
mean ratio, mean fold-change and mean P values are calculated for all
microarray elements compiled in Supplementary Data-1.2. These are then
sorted by gene ID, and each gene is represented by the microarray
element returning the lowest mean P value. This list of genes is then
checked against Zadd three-replicate responders in order to catch
disagreement among microarray elements.
Additional file 5: Final set of Zadd gene responses for all genes
that responded to any of the three treatments. This final data set
contains treatment/control ratios, fold-change values and P values, from
Zadd treatment replicates, for all transcripts that responded ≥ 2-fold, P ≤
0.01, in any of the three treatments. For any transcript that was not a
three-replicate responder in the Zadd treatment, values were derived as
described in Supplementary Data 1.1-1.4. The set of values in Excel file
“Supplementary Data 1.5.xlsx” served as the source of transcript response
values for Zadd in Figure 3. Transcript responses used in Figure 3 for
each of the other two treatments, CCM and DHA, were derived using
the same workflow.
Additional file 6: Distribution of fold change by treatment for
whole human genome transcript analysis. This figure represents the
raw distribution of fold change magnitude for all transcripts that
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Page 13 of 16exhibited fold change ≥ 2.0 (p < 0.01) in all three replicates of at least
one treatment.
Additional file 7: Possible routes to phosphorylation of p53 and
upregulated transcription of PPARg. p53 and PPARg were each used
as single beginning nodes around which to build one-step expansion
networks within MetaCore™™ version 6.3 (GeneGo).
Additional file 8: Literature annotation for transcript functional
categories in Figure 3. Numbered references included in this file match
reference numbers appearing to the right of each HGNC symbol in
Figure 3.
Additional file 9: Data represented by Figure 3. Fold change values
and associated P-values for transcripts represented in Figure 3.
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